Edition:
United Kingdom

Theratechnologies Inc (TH.TO)

TH.TO on Toronto Stock Exchange

9.60CAD
17 Aug 2018
Change (% chg)

$-0.00 (-0.00%)
Prev Close
$9.60
Open
$8.95
Day's High
$9.65
Day's Low
$8.95
Volume
148,857
Avg. Vol
201,681
52-wk High
$14.75
52-wk Low
$4.96

Latest Key Developments (Source: Significant Developments)

Theratechnologies Q2 Loss Per Share C$0.03
Thursday, 5 Jul 2018 

July 5 (Reuters) - Theratechnologies Inc ::THERATECHNOLOGIES ANNOUNCES FINANCIAL RESULTS FOR THE SECOND QUARTER OF 2018.Q2 SALES ROSE 23.1 PERCENT TO C$12.3 MILLION.Q2 LOSS PER SHARE C$0.03.  Full Article

Theratechnologies Submits Novel Single-Vial Formulation Of Egrifta For FDA Approval
Wednesday, 4 Jul 2018 

July 4 (Reuters) - Theratechnologies Inc ::THERATECHNOLOGIES SUBMITS NOVEL SINGLE-VIAL FORMULATION OF EGRIFTA® (TESAMORELIN FOR INJECTION) FOR FDA APPROVAL.THERATECHNOLOGIES INC - FILED SUPPLEMENTAL NEW DRUG APPLICATION WITH FDA FOR A SINGLE-VIAL FORMULATION OF EGRIFTA.  Full Article

Theratechnologies Announces US$50 Mln Bought Deal Offering Of Certain Notes
Wednesday, 30 May 2018 

May 30 (Reuters) - Theratechnologies Inc ::THERATECHNOLOGIES ANNOUNCES US$50 MILLION BOUGHT DEAL OFFERING OF 5.75% CONVERTIBLE UNSECURED SENIOR NOTES.THERATECHNOLOGIES - INTENDS TO USE PROCEEDS OF OFFERING TO FUND PAYMENTS DUE UNDER AMENDMENT OF EMD SERONO TERMINATION AGREEMENT.  Full Article

FDA Releases Theratechnologies From Post-Approval Commitments Related To EGRIFTA
Tuesday, 1 May 2018 

May 1 (Reuters) - Theratechnologies Inc ::FDA RELEASES THERATECHNOLOGIES FROM POST-APPROVAL COMMITMENTS RELATED TO EGRIFTA® (TESAMORELIN FOR INJECTION).THERATECHNOLOGIES - FDA DETERMINED LARGE-SCALE POST-APPROVAL TRIALS NO LONGER REQUIRED AS CURRENT LABELING ADEQUATELY REFLECTS SAFETY PROFILE OF EGRIFTA.THERATECHNOLOGIES - FOR YEAR ENDED NOV 30, 2017, CO ESTIMATED POST-APPROVAL COMMITMENTS WILL REQUIRE $13 MILLION INVESTMENT, WHICH WILL NO LONGER BE NEEDED.  Full Article

Theratechnologies Reports Q1 Loss Per Share C$0.04
Thursday, 5 Apr 2018 

April 5 (Reuters) - Theratechnologies Inc ::THERATECHNOLOGIES ANNOUNCES FINANCIAL RESULTS FOR FIRST QUARTER OF 2018.THERATECHNOLOGIES INC <<>> Q1 REVENUE C$10.22 MLN VS I/B/E/S VIEW C$10.7 MLN.THERATECHNOLOGIES INC <<>> Q1 SHR LOSS C$0.04.THERATECHNOLOGIES - AS AT FEB 28, CASH, BONDS AND MONEY MARKET FUNDS AMOUNTED TO $32.5 MLN COMPARED TO $32.9 MLN AT END OF PREVIOUS FISCAL YEAR.  Full Article

Theratechnologies Announces FDA Approval Of Trogarzo (Ibalizumab-Uiyk) Injection
Tuesday, 6 Mar 2018 

March 6 (Reuters) - Theratechnologies Inc ::THERATECHNOLOGIES ANNOUNCES FDA APPROVAL OF BREAKTHROUGH THERAPY, TROGARZO™ (IBALIZUMAB-UIYK) INJECTION, THE FIRST HIV-1 INHIBITOR AND LONG-ACTING MONOCLONAL ANTIBODY FOR MULTIDRUG RESISTANT HIV-1.  Full Article

Theratechnologies announces new data from the pivotal phase III trial of Ibalizumab
Wednesday, 15 Feb 2017 

Theratechnologies Inc : Theratechnologies announces new data from the pivotal phase III trial of HIV monoclonal antibody and long-acting investigational antiretroviral Ibalizumab . Theratechnologies - patients enrolled in phase III trial experienced significant decrease in viral load after receiving single loading dose of Ibalizumab 2,000 mg . Says no notable trends in laboratory abnormalities were observed. .Says safety results in this phase III trial are consistent with ones previously observed in phase IIB trial..  Full Article

Theratechnologies Inc Q3 EPS C$0.01
Tuesday, 4 Oct 2016 

Theratechnologies Inc : Q3 earnings per share C$0.01 . Theratechnologies announces financial results for third quarter of 2016 . Q3 sales C$8.925 million .Theratechnologies Inc - Based upon results of our Q3, our guidance for year remains unchanged.  Full Article

Theratechnologies announces financial results for third quarter of 2016
Tuesday, 4 Oct 2016 

Theratechnologies Inc : Theratechnologies announces financial results for third quarter of 2016 . Q3 earnings per share c$0.01 . Qtrly revenue was $8.9 million compared to $9.2 million . Q3 sales c$8.925 million . For twelve months ending November 30, 2016, continue to expect that net sales of egrifta to be in range of $36 million to $37 million .Expectations for adjusted EBITDA in fiscal 2016 are still in range of $5 million to $6 million.  Full Article

CANADA STOCKS-TSX futures point to higher open

June 20 Futures for Canada's main stock index were higher on Wednesday after ending down in the previous session, led by a drag in the energy sector on Tuesday.